TrialMolecular cancer2025

An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.

Anton Lahusen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.